Reports Q3 revenue $209,000, consensus $206,840. “The strength of our clinical data continues to validate our technology and reinforce our mission to redefine cancer treatment,” said Thijs Spoor, Perspective’s CEO. “With several important milestones ahead, we look forward to sharing new data and strategic updates as we close out the year and head into 2026 and beyond.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Updates Corporate Presentation on Pipeline
- Perspective Therapeutics Updates Executive Employment Agreements
- Perspective Therapeutics Advances in Neuroendocrine Tumor Therapy with Promising Clinical Study
- Perspective Therapeutics Advances Cancer Treatment with Innovative Clinical Study
- Perspective Therapeutics’ Innovative Melanoma Trial: A Potential Game-Changer